Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Holding ALNY?
Track your performance easily
ALNY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$141.98 - $304.39
Previous Close$246.8
Volume30.14K
Average Volume (3M)862.13K
Market Cap
$31.90B
Enterprise Value$30.35B
Total Cash (Recent Filing)$2.78B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Feb 06, 2025EPS Estimate
-$0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.62
Shares Outstanding128,980,917
10 Day Avg. Volume994,630
30 Day Avg. Volume862,129
Standard Deviation0.14
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)995.16
Price to Sales (P/S)14.42
Price to Cash Flow (P/CF)172.80
P/FCF Ratio191.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.49
Enterprise Value/Gross Profit20.00
Enterprise Value/Ebitda-164.55
Forecast
1Y Price Target
$313.81Price Target Upside26.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering24
Alnylam Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPositive topline Phase 3 HELIOS-B data for vutrisiran in ATTR-CM supports straightforward no-drama PRV-accelerated approval.
Market ExpansionAlnylam will expand its approved Amvuttra into the much larger cardiomyopathy indication, and Amvuttra's performance will be the primary driver of the stock.
Regulatory ApprovalHigh confidence in FDA approval of AMVUTTRA in ATTR-CM, which has blockbuster potential with $5B-plus annual revenue, reinforces the Buy rating and $400 price target on ALNY shares.
Bears Say
Market CompetitionNew diagnoses are slowing down, so the future market will be more about competition rather than expanding the pie.
Product Development And Pipeline IssuesDevelopment of ALN-KHK, an RNAi therapeutic targeting ketohexokinase for type 2 diabetes, has been suspended.
Regulatory And Reimbursement ChallengesAmvuttra is either not covered or 'effectively' not covered in several Medicare segments, disadvantaged in MAPD & non-Medicare, and advantaged in Medigap-related segments.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $141.97 and its highest was $304.39 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Feb 06, 2025 which is in 76 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Oct 31, 2024. The company reported -$0.87 earnings per share for the quarter, beating the consensus estimate of -$0.917 by $0.047.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -$0.59.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 128,980,910 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.87 in its last earnings report, beating expectations of -$0.917. Following the earnings report the stock price went down -5.293%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 996M.
---
Alnylam Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$313.81 (26.87% Upside)
$313.81 (26.87% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 237.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.53%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
ALNY Company Deck
---
ALNY Earnings Call
Q3 2024
0:00 / 0:00
---
ALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
ALNY Stock 12 Month Forecast
Average Price Target
$313.81
▲(26.87% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Moderna
―
BioMarin Pharmaceutical
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering ALNY
1 Year
1 Year Success Rate
27/37 ratings generated profit
1 Year Average Return
+26.44%
reiterated a buy rating 23 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 72.97% of your transactions generating a profit, with an average return of +26.44% per trade.
---